Exercise and breast cancer recurrence have been studied in cohorts and trial follow-ups. Encouraging findings do not prove individual prevention.
During cancer treatment, exercise can help fatigue and physical function. Those benefits differ from recurrence or survival outcomes.
What the studies actually measured
| Study | When activity was measured | Outcome | What it tells us |
|---|---|---|---|
| Holmes et al. 2005, 2,987 women in the Nurses’ Health Study | Self-reported activity after a stage I to III diagnosis, assessed a median 38 months later | Breast-cancer death was the main outcome; recurrence was a secondary analysis | More active groups had lower observed breast-cancer mortality. The recurrence analysis was observational and partly inferred recurrence from later reported metastatic disease or breast-cancer death. |
| Wilson et al. 2025, a synthesis of observational studies | Recreational aerobic activity after diagnosis, as reported in the included cohorts | Five recurrence studies included 13,977 women and 1,884 recurrences | Some activity versus none or minimal activity had a pooled hazard ratio of 0.92 (95% confidence interval 0.80 to 1.06), which includes no difference. Meeting activity guidelines had a lower observed recurrence hazard (0.80, 0.65 to 0.99), but these comparisons cannot prove a preventive effect. |
| Biganzoli et al. 2021, follow-up analyses of Australian and Canadian exercise trials | An eight-month intervention around diagnosis in 337 Australian women; supervised exercise during chemotherapy in 242 Canadian patients | Recurrence and death patterns, plus disease-free survival, which combined several event types | The Australian urban group showed a favorable later pattern, the rural group did not, and Canadian estimates were imprecise. The original trials were not designed or powered to settle recurrence risk. |
| Soldato et al. 2024, 10,359 patients in the French CANTO cohort | Self-reported exercise at diagnosis, before anticancer therapy | Distant recurrence-free interval | Activity at diagnosis had a nonlinear association with distant recurrence, and findings varied by tumor subtype. This observational study does not show that starting exercise after diagnosis prevents recurrence. |
| ASCO 2022 guideline | Trials of exercise during active cancer treatment with curative intent | Fatigue, fitness, strength and other patient-reported outcomes | These supportive outcomes justify discussing tailored exercise with the oncology team; the guideline identifies important gaps in recurrence and mortality evidence. |
Recurrence means the cancer returned after treatment. Disease-free survival is a study-defined composite that can count recurrence alongside other events, while mortality counts deaths.
A composite curve is not a recurrence count.
Why the recurrence answer remains uncertain
Holmes did not randomly assign activity. Health differences between active and less active participants can remain after statistical adjustment.
Breast-cancer mortality was the main outcome. Secondary recurrence events were partly inferred from distant cancer reports and the timing of breast-cancer deaths, limiting their reliability.
Wilson’s observational comparisons do not establish an individual preventive effect.
Biganzoli’s randomized-trial follow-up remains exploratory. It reanalyzed published figures, not original patient records.
CANTO measured pretreatment activity at diagnosis, not an assigned exercise change. Its analysis of activity changes over time found no association with distant recurrence, although a smaller sample limited inference.
One fictional example shows why the endpoint matters
Imagine a study that explicitly defines its composite endpoint as recurrence, a new primary cancer or death. If four different participants have two recurrences, one new primary and one unrelated death, that would be four composite events, not four recurrences.
This is an invented arithmetic illustration, not data from any study above. Another paper may define disease-free survival differently, so its own endpoint definition must come first.
The lesson is to keep the event label attached to every percentage or curve. A result can matter without answering the exact question of how often the original breast cancer returned.
What exercise is better supported for
The 2022 ASCO guideline recommends that oncology providers discuss regular aerobic and resistance exercise during active treatment with curative intent to mitigate side effects. Across the trials it reviewed, exercise helped fatigue, cardiorespiratory fitness, physical functioning, and strength, with some quality-of-life benefits.
Supportive benefits matter, but a fatigue or fitness outcome is not a measure of cancer returning.
A discussion guide for your oncology team
These are questions for interpreting research with your oncology team, not an exercise program, a risk calculator or instructions to change cancer care:
- Was activity measured before diagnosis, during treatment or afterward?
- Does the result concern recurrence, a composite study endpoint, death or a supportive outcome such as fatigue?
- Were participants assigned to an exercise intervention, or were existing activity patterns observed?
- How similar was the study population to my situation, and which limits matter?
- What role, if any, should exercise support have in my existing care plan?
The featured picture is an illustration of activity, not a demonstration for surgery recovery or proof that the observer is a clinician. It does not establish which movement, load or range is appropriate for a person receiving cancer care.
The takeaway
Keep recurrence, survival and supportive benefits separate when reading a study. Ask your oncology team which design, measurement timing and limitations matter for your care.
Get the next evidence check.
Five practical fitness stories worth your time, every Friday.
One email a week. No product pitches. Unsubscribe in one click.
Sources
- Holmes et al. 2005, postdiagnosis activity and survival cohort with secondary recurrence analysis.
- Wilson et al. 2025, postdiagnosis aerobic exercise and breast-cancer recurrence and mortality review of observational studies.
- Biganzoli et al. 2021, recurrence-dynamics follow-up analysis of exercise trials.
- Soldato et al. 2024, exercise at diagnosis and distant recurrence-free interval in the CANTO cohort.
- ASCO 2022 exercise guideline.
Medical disclaimer: This article is general fitness and research information, not cancer treatment or an individual exercise plan. Your oncology team can help interpret these studies in light of your diagnosis, treatment and current health.





